Publications in collaboration with researchers from Hospital Morales Meseguer (11)

2023

  1. A correlative biomarker study and integrative prognostic model in chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide

    Prostate, Vol. 83, Núm. 4, pp. 376-384

2022

  1. Corrigendum to “589P Dynamics of peripheral blood immune profiling associated with tumour progression in metastatic castration resistant prostate cancer (mCRPC)”: [Annals of Oncology 32 suppl. 5 (2021) S637-S638] (Annals of Oncology (2021) 32 suppl. 5(S637-S638) (S0923753421033317), (10.1016/j.annonc.2021.08.1102))

    Annals of Oncology

2021

  1. A Risk-benefit Analysis of Prophylactic Anticoagulation for Patients with Metastatic Germ Cell Tumours Undergoing First-line Chemotherapy

    European Urology Focus, Vol. 7, Núm. 5, pp. 1130-1136

2020

  1. Large retroperitoneal lymphadenopathy and increased risk of venous thromboembolism in patients receiving first-line chemotherapy for metastatic germ cell tumors: A study by the global germ cell cancer group (G3)

    Cancer Medicine, Vol. 9, Núm. 1, pp. 116-124

2018

  1. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE)

    Oncologist, Vol. 23, Núm. 4, pp. 422-432

2017

  1. Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: A multi-institution correlative biomarker study

    Annals of Oncology, Vol. 28, Núm. 7, pp. 1-9

  2. Consensus Recommendations from the Spanish Germ Cell Cancer Group on the Use of High-dose Chemotherapy in Germ Cell Cancer

    European Urology Focus, Vol. 3, Núm. 2-3, pp. 280-286

  3. Prognostic significance of venous thromboembolic events in disseminated germ cell cancer patients

    Journal of the National Cancer Institute, Vol. 109, Núm. 4

  4. Strategies to design clinical studies to identify predictive biomarkers in cancer research

    Cancer Treatment Reviews, Vol. 53, pp. 79-97

2012

  1. Recomendations on the management of controversies in advanced castrate-resistant prostate cancer

    Actas Urologicas Espanolas, Vol. 36, Núm. 10, pp. 569-577

2009

  1. Long-term follow-up of an anthracycline-containing metronomic chemotherapy schedule in advanced breast cancer

    Breast Journal